Argos Therapeutics Presents New Phase 2 Data Showing its Arcelisâ¢ Immunotherapy AGS-003 in Combination with sunitinib Improves Progression-Free Survival (PFS) in Patients with Advanced Renal Cell Carcinoma (RCC)